文献速递脊柱关节炎其他结缔组织病

幼年附着点炎相关关节炎与成人脊柱关节炎治疗益处可能相关

Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis.
PubMed 文献 · Arthritis Care Res (Hoboken) · 2022-04-15

本综述总结幼年附着点炎相关关节炎(ERA)与成人中轴型及外周型脊柱关节炎(SpA)在临床、遗传和病理生理特征上的共性。由于分类标准差异,FDA曾对儿童中轴型脊柱关节炎研究自动豁免,导致已获批成人SpA的生物制剂未在ERA患儿中研究或标注。作者建议应在活动性ERA患儿中研究这些药物并推动儿童适应症标注。

要点

  • ERA与成人SpA在病因、遗传、发病机制和临床表现上存在相似性。
  • FDA曾对儿童中轴型脊柱关节炎研究自动豁免至2020年7月。
  • 已获批成人外周型或非放射学中轴型SpA的药物未在ERA患儿中研究或标注。

核心结论

  • 基于ERA与成人SpA的相似性,已获批用于中轴型或外周型SpA的药物应在相应关节受累的活动性ERA患儿中研究,以期获得儿童适应症标注。
  • 鉴于目前缺乏FDA批准的有效ERA疗法,FDA应考虑要求已获批成人SpA药物开展儿科研究。

研究设计与样本

  • 本文为综述,总结ERA与成人中轴型及外周型SpA共享的临床、遗传和病理生理特征。

主要发现

  • ERA与成人中轴型SpA(非放射学及部分放射学)以及外周型SpA在病因、遗传、发病机制和临床表现上存在相似性。
  • 由于儿童ERA与成人SpA分类标准不同,FDA对「包括强直性脊柱炎的中轴型脊柱关节炎」新药儿童研究自动完全豁免至2020年7月。
  • 当前幼年特发性关节炎治疗指南推荐生物制剂改善病情抗风湿药作为ERA早期治疗的一部分,但FDA批准用于外周型SpA或非放射学中轴型SpA的疗法(certolizumab pegol、ixekizumab、secukinumab)均未在ERA患儿中研究或标注。

临床怎么用

  • 临床应认识到ERA与成人SpA的相似性,支持在活动性ERA患儿中研究已获批成人SpA的药物。
  • 推动已获批成人SpA药物开展儿科研究并获取儿童适应症标注,以弥补ERA有效FDA批准疗法的缺乏。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

This review will summarize clinical, genetic, and pathophysiologic characteristics that are shared between children with enthesitis-related arthritis (ERA) with axial involvement and adults with nonradiographic (and in some cases radiographic) axial spondyloarthritis (SpA), as well as between children with ERA and primarily peripheral disease manifestations and adults with peripheral SpA. Due to the differences in classification criteria for children with ERA and adults with axial and peripheral SpA, the US Food and Drug Administration (FDA) granted automatic full waivers of studies in children for new medications for "axial spondyloarthropathies including ankylosing spondylitis" up until July 2020. Thus, although current juvenile idiopathic arthritis treatment guidelines recommend the use of biologic disease-modifying antirheumatic drugs as part of the early treatment for patients with ERA, none of the FDA-approved therapies for peripheral SpA or nonradiographic axial SpA (certolizumab pegol, ixekizumab, and secukinumab) have been studied or are labeled for use in children with ERA. Considering the similarities between adult SpA and ERA in terms of etiology, genetics, pathogenesis, and clinical manifestations summarized in this review, medications approved for axial SpA or peripheral SpA should also be studied in children with active ERA involving axial or peripheral joints, respectively, with the intent to achieve labeling for use in children. Considering the current lack of effective FDA-approved therapies for ERA, the FDA should also consider requiring pediatric studies for medications that have already been approved for the treatment of adults with SpA.

来源:Arthritis Care Res (Hoboken),查看原文。版权归原作者所有。

引用

  1. Weiss PF, Fuhlbrigge RC, von Scheven E, et al. Children With Enthesitis-Related Arthritis and Possible Benefits From Treatments for Adults With Spondyloarthritis. Arthritis Care Res (Hoboken). 2022. PMID: 33278336. doi:10.1002/acr.24529

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。